DOP2012000209A - Compuesto para suprimir un trastorno del nervio periférico inducido por un agente anticancerígeno - Google Patents
Compuesto para suprimir un trastorno del nervio periférico inducido por un agente anticancerígenoInfo
- Publication number
- DOP2012000209A DOP2012000209A DO2012000209A DO2012000209A DOP2012000209A DO P2012000209 A DOP2012000209 A DO P2012000209A DO 2012000209 A DO2012000209 A DO 2012000209A DO 2012000209 A DO2012000209 A DO 2012000209A DO P2012000209 A DOP2012000209 A DO P2012000209A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- peripheral nerve
- delete
- composite
- nerve disorder
- disorder induced
- Prior art date
Links
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 206010060860 Neurological symptom Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010015935 | 2010-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2012000209A true DOP2012000209A (es) | 2012-12-31 |
Family
ID=43770309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2012000209A DOP2012000209A (es) | 2010-01-27 | 2012-07-25 | Compuesto para suprimir un trastorno del nervio periférico inducido por un agente anticancerígeno |
Country Status (41)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428477B2 (en) * | 2012-04-27 | 2016-08-30 | Nippon Zoki Pharmaceutical Co., Ltd. | Trans-2-decenoic acid derivative and drug containing same |
| CN105934253A (zh) * | 2013-12-17 | 2016-09-07 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法 |
| JP6718884B2 (ja) | 2015-05-08 | 2020-07-08 | 武田薬品工業株式会社 | 環状化合物 |
| KR102689256B1 (ko) | 2015-06-17 | 2024-07-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
| RU2742337C2 (ru) * | 2016-09-09 | 2021-02-04 | Такеда Фармасьютикал Компани Лимитед | Циклическое соединение |
| WO2019047812A1 (zh) * | 2017-09-07 | 2019-03-14 | 深圳信立泰药业股份有限公司 | 多西他赛共缀物的药物组合物及制备方法 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
| US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| EP0252146B1 (en) | 1986-01-09 | 1994-05-25 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| WO1988005083A1 (en) | 1986-12-24 | 1988-07-14 | Whitehead Institute For Biomedical Research | Method of inducible gene expression |
| WO1989007614A1 (en) | 1988-02-12 | 1989-08-24 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| EP0407411B1 (en) | 1988-03-01 | 1993-11-10 | Whitehead Institute For Biomedical Research | ACTIVITION OF NF-kB PRECURSOR |
| US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| EP0465565B1 (en) | 1989-03-31 | 1996-05-15 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5158883A (en) | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
| US5059712A (en) | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
| WO1992003137A1 (en) | 1990-08-23 | 1992-03-05 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
| WO1992017168A1 (en) | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
| US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| ATE182076T1 (de) | 1991-04-19 | 1999-07-15 | Childrens Medical Center | Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden |
| US6071876A (en) | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
| MX9709442A (es) * | 1995-06-07 | 1998-02-28 | Sugen Inc | Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa. |
| US20020052019A1 (en) | 1997-11-13 | 2002-05-02 | Genentech Inc | Human toll homologue |
| US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
| ATE381574T1 (de) | 1997-10-17 | 2008-01-15 | Genentech Inc | Menschliche toll-homologe |
| ZA989147B (en) | 1997-10-17 | 2000-04-07 | Genentech Inc | Human toll homologues. |
| US20080275104A1 (en) | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| US20040072138A1 (en) | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| AU1539399A (en) | 1997-11-25 | 1999-06-15 | Medical University Of South Carolina | Inhibitors of nitric oxide synthase |
| EP1063228B1 (en) | 1998-03-09 | 2005-01-19 | Takeda Pharmaceutical Company Limited | Cycloalkene derivatives, process for producing the same, and use |
| DE60045033D1 (de) | 1999-08-06 | 2010-11-11 | Takeda Pharmaceutical | Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung |
| SE9903930D0 (sv) * | 1999-10-29 | 1999-10-29 | Astra Pharma Inc | Novel compounds and a novel process for their preparation |
| CN1416341B (zh) | 2000-02-04 | 2010-05-05 | 武田药品工业株式会社 | 稳定的乳液组合物 |
| AU6488901A (en) | 2000-05-25 | 2001-12-03 | Schering Corp | Human receptor proteins; related reagents and methods |
| CA2685447C (en) | 2000-08-10 | 2013-05-28 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| DE60144570D1 (de) | 2000-10-18 | 2011-06-16 | Takeda Pharmaceutical | Verfahren zur herstellung von optisch aktiven sulfonamiden und zwischenprodukte zur deren synthese |
| JP4498678B2 (ja) | 2000-11-30 | 2010-07-07 | 株式会社トクヤマ | 基板およびその製造方法 |
| AU2002221099A1 (en) | 2000-12-08 | 2002-06-18 | Takeda Chemical Industries Ltd. | Combination drugs |
| JP5137289B2 (ja) | 2001-08-03 | 2013-02-06 | 武田薬品工業株式会社 | 安定な乳化組成物 |
| WO2003084527A1 (en) | 2002-04-08 | 2003-10-16 | Takeda Chemical Industries, Ltd. | Severe sepsis preventive therapeutic agent |
| US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| WO2004074435A2 (en) | 2003-01-30 | 2004-09-02 | Emory University | Methods for identifying and administering agents that bias the immune response via dendritic cells |
| WO2004075865A2 (en) | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
| JP2006523452A (ja) | 2003-03-25 | 2006-10-19 | スリーエム イノベイティブ プロパティズ カンパニー | 共通のＴｏｌｌ様受容体を通じて媒介される細胞活性の選択的活性化 |
| JP2007505629A (ja) | 2003-09-17 | 2007-03-15 | スリーエム イノベイティブ プロパティズ カンパニー | Ｔｌｒ遺伝子発現の選択的調節 |
| US8034619B2 (en) | 2003-12-19 | 2011-10-11 | University Of Cincinnati | Polyamides for nucleic acid delivery |
| TWI462745B (zh) | 2005-04-28 | 2014-12-01 | Takeda Pharmaceutical | 安定的乳化組成物 |
| BRPI0611079A2 (pt) | 2005-06-03 | 2010-08-03 | Ono Pharmaceutical Co | agentes para a regeneração e/ou proteção de nervos |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| US20090175835A1 (en) | 2006-02-07 | 2009-07-09 | Korea Institute Of Radiological & Medical Sciences | Composition for treating damage of central or peripheral nerve system |
| US7985538B2 (en) | 2006-02-23 | 2011-07-26 | Yale University | Drug resistance and methods of reversing |
| US7943588B2 (en) | 2006-03-28 | 2011-05-17 | Trustees Of Dartmouth College | Method for preventing or treating neuropathic pain |
| WO2007114296A1 (ja) | 2006-03-30 | 2007-10-11 | Hiroshima University | スクリーニング方法 |
| WO2007123186A1 (ja) * | 2006-04-20 | 2007-11-01 | Takeda Pharmaceutical Company Limited | 医薬 |
| JPWO2007132825A1 (ja) | 2006-05-15 | 2009-09-24 | 武田薬品工業株式会社 | 医薬 |
| US20090209585A1 (en) | 2006-07-07 | 2009-08-20 | Takashi Ichikawa | Cycloalkene derivatives, process for production of the derivatives, and use of the same |
| EP1882687A1 (en) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same |
| WO2008112887A1 (en) | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| WO2009059050A2 (en) | 2007-10-30 | 2009-05-07 | The Regents Of The University Of Colorado | Tlr modulators and methods for using the same |
| WO2009145814A2 (en) | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| JP5238381B2 (ja) | 2008-07-07 | 2013-07-17 | スタンレー電気株式会社 | 照明用車両用灯具 |
| CA2774008C (en) | 2009-09-23 | 2017-06-20 | The Regents Of The University Of Colorado, A Body Corporate | Toll-like receptor modulators and uses thereof |
-
2011
- 2011-01-26 MY MYPI2012003414A patent/MY163936A/en unknown
- 2011-01-26 CN CN201180015681.3A patent/CN102821763B/zh not_active Expired - Fee Related
- 2011-01-26 TW TW100102774A patent/TWI481401B/zh not_active IP Right Cessation
- 2011-01-26 WO PCT/JP2011/052077 patent/WO2011093512A1/en not_active Ceased
- 2011-01-26 HU HUE11705047A patent/HUE027310T2/en unknown
- 2011-01-26 DK DK11705047.6T patent/DK2528598T3/en active
- 2011-01-26 SI SI201130755T patent/SI2528598T1/sl unknown
- 2011-01-26 RS RS20160076A patent/RS54591B1/sr unknown
- 2011-01-26 EP EP11705047.6A patent/EP2528598B1/en active Active
- 2011-01-26 AR ARP110100247A patent/AR080024A1/es unknown
- 2011-01-26 UY UY0001033203A patent/UY33203A/es not_active Application Discontinuation
- 2011-01-26 NZ NZ601635A patent/NZ601635A/xx not_active IP Right Cessation
- 2011-01-26 KR KR1020127021846A patent/KR20120118044A/ko not_active Abandoned
- 2011-01-26 SG SG10201503402XA patent/SG10201503402XA/en unknown
- 2011-01-26 ME MEP-2016-31A patent/ME02364B/me unknown
- 2011-01-26 HR HRP20160165TT patent/HRP20160165T1/hr unknown
- 2011-01-26 BR BR112012018434A patent/BR112012018434A2/pt not_active IP Right Cessation
- 2011-01-26 PL PL11705047T patent/PL2528598T3/pl unknown
- 2011-01-26 JP JP2012533416A patent/JP6131046B2/ja active Active
- 2011-01-26 ES ES11705047.6T patent/ES2560215T3/es active Active
- 2011-01-26 CA CA2788150A patent/CA2788150C/en not_active Expired - Fee Related
- 2011-01-26 PH PH1/2012/501538A patent/PH12012501538A1/en unknown
- 2011-01-26 CN CN201510072433.2A patent/CN104744321A/zh active Pending
- 2011-01-26 MA MA35162A patent/MA34014B1/fr unknown
- 2011-01-26 GE GEAP201112845A patent/GEP20166441B/en unknown
- 2011-01-26 EA EA201290697A patent/EA201290697A1/ru unknown
- 2011-01-26 AU AU2011211294A patent/AU2011211294B2/en not_active Ceased
- 2011-01-26 UA UAA201210137A patent/UA109540C2/uk unknown
- 2011-01-26 PE PE2012001062A patent/PE20121694A1/es not_active Application Discontinuation
- 2011-01-26 PT PT117050476T patent/PT2528598E/pt unknown
- 2011-01-26 US US13/574,848 patent/US20130046000A1/en not_active Abandoned
- 2011-01-26 SG SG2012051967A patent/SG182522A1/en unknown
- 2011-01-26 MX MX2012008514A patent/MX2012008514A/es not_active Application Discontinuation
-
2012
- 2012-07-17 TN TNP2012000364A patent/TN2012000364A1/en unknown
- 2012-07-23 IL IL221066A patent/IL221066A/en not_active IP Right Cessation
- 2012-07-25 DO DO2012000209A patent/DOP2012000209A/es unknown
- 2012-07-26 CL CL2012002079A patent/CL2012002079A1/es unknown
- 2012-07-27 ZA ZA2012/05681A patent/ZA201205681B/en unknown
- 2012-08-07 CR CR20120412A patent/CR20120412A/es unknown
- 2012-08-17 CO CO12140288A patent/CO6592110A2/es not_active Application Discontinuation
- 2012-08-27 EC ECSP12012126 patent/ECSP12012126A/es unknown
-
2013
- 2013-08-20 US US13/971,159 patent/US8901171B2/en not_active Expired - Fee Related
-
2014
- 2014-10-28 US US14/525,576 patent/US20150051256A1/en not_active Abandoned
-
2015
- 2015-04-02 US US14/676,947 patent/US20150203464A1/en not_active Abandoned
-
2016
- 2016-02-19 US US15/047,965 patent/US20160166526A1/en not_active Abandoned
- 2016-03-04 CY CY20161100189T patent/CY1117268T1/el unknown
- 2016-03-18 JP JP2016056186A patent/JP2016175903A/ja active Pending
- 2016-04-12 SM SM201600103T patent/SMT201600103B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012644A (es) | Tratamiento de cataplejia. | |
| GT201500093A (es) | Moduladores de quinolinilo unidos a metileno de ror- gamma-t | |
| GT201400191A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| MX2014010481A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| CO2018000809A2 (es) | Anticuerpos para cd40 | |
| MX2016001236A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MX2021003858A (es) | Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. | |
| ES2877502T8 (es) | Uso del fitocannabinoide cannabidiol (CBD) en combinación con un fármaco antiepiléptico estándar (SAED) en el tratamiento de la epilepsia | |
| MX372669B (es) | Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer. | |
| BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
| DOP2012000209A (es) | Compuesto para suprimir un trastorno del nervio periférico inducido por un agente anticancerígeno | |
| MX2019009283A (es) | Composiciones de arni de proteina convertasa subtilisina kexina 9 (pcsk9) y metodos de uso de las mismas. | |
| CR20150216A (es) | Composiciones y métodos para tratar proteinopatías | |
| CO7101239A2 (es) | Composiciones derivadas de la quitosana | |
| ES2569743R1 (es) | Uso de la buprenorfina en la fabricación de un medicamento para tratar los efectos secundarios inducidos por opioides | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| AR094318A1 (es) | Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o enfermedad cognitivo, neurodegenerativo o neuronal | |
| MX2015011371A (es) | Anticuerpos monoclonales anti-+)--metanfetamina. | |
| BR112014030992A2 (pt) | composições compreendendo calcogenetos e métodos relacionados | |
| CL2015003668A1 (es) | Método de tratamiento de trastornos neurodegenerativos. | |
| BR112016012067A2 (pt) | composto para o tratamento de hipo¬glicemia grave | |
| IN2014KN01772A (cg-RX-API-DMAC7.html) | ||
| IN2014KN02952A (cg-RX-API-DMAC7.html) | ||
| IN2013MU02469A (cg-RX-API-DMAC7.html) | ||
| MY184721A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis |